Jay Pharma Inc, a company dedicated to developing innovative, evidence-based medicines and combination therapies to address unmet needs in cancer care, has named George A Kegler, Jr as its new director and as audit committee chair, it was reported on Thursday.

Kegler is a former executive at Mallinckrodt plc, where he previously held positions of segment controller, division controller and served as interim chief financial officer. He earlier served as chief financial officer of Convatec, a spin-out from Bristol Myers Squibb to private equity groups.

Dave Johnson, who plans to join Jay Pharma as chairman and CEO upon the closing of the Ameri merger transa, said, 'Mr. Kegler will offer strong financial expertise to Jay Pharma as we build a world-class board of directors with relevant skills and experience. His decades-long healthcare business knowledge will be an incredible asset to our team, and we believe he will add immense value as future Chair of Jay Pharma's Audit Committee, while helping to build a foundation to support and propel Jay Pharma's rapid expansion.'